Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. The Rockwell Medical (RMTI) news feed on Stock Titan focuses on company announcements that relate to its hemodialysis concentrates portfolio, supply agreements with dialysis providers, operational updates, and financial results.
Investors and healthcare observers following RMTI news can expect coverage of product purchase agreements with large dialysis providers, health systems, and specialized care organizations. Recent company communications describe multi-year contracts that include utilization or purchase minimums, options to renew, and supply of liquid and dry acid and bicarbonate concentrates, as well as Rockwell Medical’s dry acid concentrate mix system and bicarbonate cartridge. News items also highlight the company’s efforts to expand its customer base, including adding new dialysis customers in different regions of the United States.
The RMTI news stream also includes quarterly financial and operational results, typically released through earnings press releases and accompanied by conference call details. These updates discuss net sales, gross margin, adjusted EBITDA, and cash position, along with commentary on customer transitions, contract renewals, and manufacturing efficiency. In addition, Rockwell Medical issues news on leadership changes, such as board appointments and executive promotions, and on operational roles related to manufacturing and supply chain management.
Further topics in Rockwell Medical news include participation in industry events, such as exhibiting its hemodialysis concentrates portfolio at professional nephrology conferences, and recognition as a Great Place to Work® and a Fortune Best Workplaces in Manufacturing & Production™ honoree. For users tracking RMTI, this news page provides a centralized view of the company’s corporate developments, financial disclosures, and updates on its hemodialysis products and customer relationships.
Rockwell Medical (Nasdaq: RMTI), a healthcare company focused on hemodialysis products, has scheduled its Q4 and full-year 2024 financial results release for Thursday, March 20, 2025. The company will issue a press release at 6:00am ET, followed by a live conference call and webcast at 8:00am ET.
The earnings call will feature presentations from key executives including President and CEO Mark Strobeck, Ph.D., CFO Jesse Neri, and Chief Commercial Officer Tim Chole. The discussion will cover financial and operational results, followed by a Q&A session.
Rockwell Medical (RMTI) has entered into a distribution services agreement to add single-use bicarbonate cartridges to its hemodialysis product portfolio. The agreement enables RMTI to distribute 510(k) approved bicarbonate cartridges in two sizes (720g and 900g) to dialysis centers, hospital-based outpatient centers, and skilled nursing facilities.
The single-use bicarbonate disposables market represents an approximate $100 million opportunity and is one of the fastest-growing segments within the hemodialysis concentrates market. The company plans to launch the product in late February 2025, leveraging its existing distribution network and transportation subsidiary.
Rockwell Medical (RMTI) has signed a significant product purchase agreement with the world's leading dialysis products and services provider. The agreement covers the supply of SteriLyte®, Rockwell's liquid bicarbonate hemodialysis concentrates product. The partnership is expected to generate over $10 million in net sales for Rockwell in 2025, with incremental price increases in subsequent years.
The agreement has an initial term of three years with the option to extend for two additional one-year periods. Rockwell Medical, as the leading supplier of liquid bicarbonate in the United States, is currently the only manufacturer capable of producing liquid bicarbonate at a scale supporting major U.S.-based dialysis providers.
Rockwell Medical (Nasdaq: RMTI) has promoted Jesse Neri to Chief Financial Officer. Neri, who joined the company in October 2023 as SVP of Finance, brings nearly 25 years of financial leadership experience in both public and private companies. Prior to Rockwell, he served as Executive Director of Finance at Hemavant Sciences and Aruvant Sciences, and as Senior Vice President of Finance at Zyla Life Sciences, where he managed a $80 million revenue operation and led various strategic initiatives including product acquisitions and commercial launches.
Rockwell Medical (RMTI) has announced a partnership with HydroCare, a provider of dialysis water treatment systems, to distribute and install Rockwell's dry acid concentrate mix system in dialysis water rooms. The partnership involves HydroCare purchasing and installing Rockwell's DAMX45 system, which is 510(k) approved for exclusive use with the company's CitraPure® and Dri-Sate® dry acid concentrate powders.
The DAMX45 system features a forced RO water pump that can mix 100 gallons of acid concentrate on-site in three minutes. This collaboration is expected to generate new sales for Rockwell's dry acid hemodialysis concentrates through expanded mixer installations.
Rockwell Medical (Nasdaq: RMTI) has entered into an exclusive distribution agreement with Nephro Group Dialysis Centers, the largest dialysis provider in the Philippines. Under the agreement, Rockwell Medical will be the exclusive supplier of dry hemodialysis concentrates products, including CitraPure® Acid and RenalPure® Bicarbonate. Nephro Group, founded in 1995, has grown to become the Philippines' largest dialysis provider. This expansion adds to Rockwell Medical's international presence, which now spans over 30 countries across North America, South America, Asia, and Africa.
Rockwell Medical (RMTI) reported strong Q3 2024 financial results with net product sales of $28.3 million, up 31% year-over-year. The company achieved gross profit of $6.2 million (183% increase) and a gross margin of 22%. Notable highlights include $4.3 million in cash flow from operations and net income of $1.7 million. The company increased its 2024 guidance, projecting net sales of $98-101 million and Adjusted EBITDA of $4-5 million. However, their largest customer indicated expected volume declines in 2025, potentially reducing sales by $31-38 million.
Rockwell Medical (Nasdaq: RMTI) has rescheduled its third quarter 2024 earnings release and conference call to Tuesday, November 12, 2024, due to SEC EDGAR system closure on November 11 for Veterans Day. The company will issue its financial and operational results press release at 6:00am ET, followed by a live conference call and webcast at 8:00am ET. The call will discuss Q3 2024 results and include a Q&A session.
Rockwell Medical, Inc. (Nasdaq: RMTI), a healthcare company specializing in hemodialysis products, has announced the release of its third quarter 2024 financial and operational results on Monday, November 11, 2024. The company will issue a press release at 6:00am ET, followed by a live conference call and webcast at 8:00am ET.
The conference call details are as follows:
- Date: Monday, November 11, 2024
- Time: 8:00am ET
- Live Number: (888) 660-6347 (US) / 1 (929) 201-6594 (International)
- Conference Call ID: 4944610
- Webcast and Replay: www.RockwellMed.com/Results
Rockwell Medical, Inc. (Nasdaq: RMTI), a healthcare company specializing in hemodialysis products, has been recognized as one of the 2024 Fortune Best Workplaces in Manufacturing and Production in the small & medium category. This prestigious acknowledgment comes from Great Place to Work® and Fortune magazine.
Lesley Spriggs, Vice President of Human Resources at Rockwell Medical, expressed pride in the company's achievement, highlighting the dedication of their leadership and employees. The company's focus on manufacturing and delivering life-sustaining dialysis solutions for patients with end-stage kidney disease has been a key factor in this recognition.